Palovarotene FDA Approval Status
FDA Approved: No
Generic name: palovarotene
Company: Ipsen Biopharmaceuticals, Inc.
Treatment for: Fibrodysplasia Ossificans Progressiva
Palovarotene is an oral, investigational, selective RARγ agonist in development for the prevention of heterotopic ossification as a potential treatment option for people with fibrodysplasia ossificans progressiva (FOP).
Development timeline for palovarotene
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.